Genome Therapy: How Genetic Treatments Work

Genome therapy, often called gene therapy, is a form of genetic medicine designed to address disease by adding, correcting, silencing or editing genetic material in cells. It is used for a limited but growing range of inherited disorders, cancers and other serious conditions, with the procedure and recovery varying by treatment type.

Genome Therapy: an overview

Genome therapy is a broad term for medical treatments that use genetic material to help prevent, treat or manage disease. It is commonly referred to as gene therapy, although some approaches involve gene editing or genetically modified cells. Rather than treating only the effects of a condition, these therapies aim to address a biological cause at the level of DNA, RNA or cell function.

Depending on the condition, a therapy may provide a working copy of a gene, reduce the activity of a harmful gene, instruct cells to make a useful protein or precisely alter DNA in selected cells. Genome therapy is not one standard procedure. Each approved treatment and clinical trial has its own eligibility criteria, preparation, monitoring plan and expected outcomes.

Many genome therapies are designed for serious inherited diseases with few effective options. Others are used in cancer care, where a patient’s immune cells may be genetically modified to recognize cancer cells. These treatments are highly specialized and are delivered by experienced multidisciplinary teams.

How genome therapy works

Genes contain instructions that help cells make proteins and perform essential tasks. A genetic change may lead to too little of a protein, an altered protein, or a protein that functions in a way that causes illness. Genome therapy seeks to change this pathway. It does not necessarily remove every effect of a condition, and it is not appropriate for every genetic disease.

One common method uses a modified virus, called a vector, to carry genetic instructions into target cells. The vector is altered so that it does not cause the original viral illness. Other methods involve collecting blood or bone marrow stem cells, changing them in a laboratory and infusing them back into the person. Gene-editing approaches may alter a specific DNA sequence in cells, usually under carefully controlled conditions.

The treatment can be delivered directly into the body, known as in vivo therapy, or performed on cells outside the body, known as ex vivo therapy. The choice depends on where the affected cells are located, the disease mechanism and the therapy’s established safety and effectiveness.

• Gene addition: supplies a functional genetic instruction.
• Gene silencing: reduces production of a harmful protein.
• Gene editing: changes DNA in particular cells.
• Cell-based gene therapy: modifies a person’s cells to restore function or target disease.

Procedure and preparation

Before genome therapy, the care team confirms the diagnosis and identifies the relevant genetic change when appropriate. Assessment commonly includes a medical history, physical examination, blood tests, organ-function testing and discussion of prior treatments. Genetic counselling may help patients and families understand what the result means, how a therapy works and whether relatives could also be affected.

The procedure differs greatly between products. An infusion-based therapy may be given through a vein in a specialist hospital setting, with observation during and after the infusion. For therapies using a patient’s own cells, cells are first collected from blood or bone marrow. They are modified and tested in a laboratory, then returned by infusion after the patient has received any required preparatory treatment.

Some cell-based therapies require conditioning chemotherapy to create space in the bone marrow for the modified cells. This is different from chemotherapy used to destroy cancer, although the medicines can have overlapping effects. The medical team explains why preparation is needed, the likely short-term effects and the practical arrangements for hospital care.

Patients should tell their team about all medicines, supplements, allergies, vaccinations, current infections and pregnancy plans. They should also ask about travel, caregiver support, expected hospital stay, infection precautions and the planned schedule for long-term reviews.

Recovery, monitoring and possible side effects

Recovery depends on the treatment route and the underlying condition. After a one-time infusion, some people may be monitored for hours or days for infusion reactions. Recovery after cell-based genome therapy can take longer because cell collection, conditioning and blood-count recovery may be involved. Some patients need a period of inpatient care, while others can be monitored as outpatients.

Possible side effects vary. They may include fever, fatigue, nausea, headache, changes in blood counts, liver test abnormalities or immune reactions. Preparatory chemotherapy can temporarily lower blood counts and increase infection risk. In cancer-directed cell therapies, immune activation can occasionally produce serious inflammation, so close monitoring in an experienced center is essential.

Long-term follow-up is a standard part of many genome therapy programs. The team may monitor symptoms, blood tests, organ function and evidence that the treatment is working. They also watch for delayed effects, as the long-term safety profile of newer therapies continues to be studied.

Patients should follow individualized advice on medicines, infection prevention, activity, diet and vaccinations. They should not stop prescribed treatment or assume that genome therapy has removed the need for routine follow-up without guidance from their specialist.

What is the success rate of gene therapy?

There is no single success rate for gene therapy. Outcomes vary widely according to the disease, the specific genetic change, the type of therapy, the person’s health before treatment and how “success” is defined. In some conditions, success may mean preventing severe complications, reducing transfusion needs, improving mobility or slowing disease progression rather than producing a complete cure.

Clinical trial and real-world results for approved therapies can be encouraging, but they may involve relatively small groups and limited years of follow-up. A specialist can explain the evidence for a particular therapy, including how many people benefited, how long benefits have lasted and what uncertainties remain.

It is important to distinguish between an individual response and population-level results. A treatment that works very well for many eligible patients may still not work equally well for everyone, and adverse effects can influence whether it is suitable for a particular person.

What diseases have been cured with gene therapy?

The word “cured” should be used carefully. Some gene therapies can produce long-lasting correction of a disease process or major improvement in selected patients, but long-term data may still be developing. Inherited blood disorders, certain immune deficiencies, some inherited eye diseases and selected neuromuscular conditions are among the areas where gene-based treatments have been developed or approved in some countries.

For example, gene-based approaches may substantially reduce severe symptoms in some people with sickle cell disease or transfusion-dependent beta thalassemia. They can also restore important immune function in certain inherited immune deficiencies. However, outcomes, eligibility and availability differ by country, and a person may still need ongoing medical monitoring.

Genome therapy is also used in some cancers through genetically modified immune-cell treatments. These therapies may lead to remission in certain blood cancers, but remission is not always permanent and cannot be predicted for an individual. For inherited blood conditions, evaluation may be coordinated with specialists in blood disorders to clarify diagnosis and treatment options.

Is gene therapy better than chemotherapy?

Gene therapy is not simply better or worse than chemotherapy; the two treatments have different purposes. Chemotherapy is a broad term for medicines that can kill or slow rapidly dividing cells. It is commonly used to treat cancer and may also be used as conditioning before certain stem-cell or gene-based therapies.

Gene therapy may be considered when it targets a known genetic cause or when modified immune cells can help recognize cancer. In some situations, it may reduce reliance on ongoing conventional treatment. In others, chemotherapy remains the most established, effective or appropriate option, either on its own or as part of a combined treatment plan.

The right approach depends on diagnosis, disease stage, genetic findings, previous treatment, overall health and personal priorities. A qualified oncology, hematology or genetics team can compare expected benefits, side effects, recovery and uncertainty for each option.

Is gene therapy painful?

Genome therapy itself is usually not described as painful in the same way as surgery. Infusions are given through an intravenous line, which may cause brief discomfort when it is inserted. Blood draws, injections, cell collection procedures or bone marrow procedures may also cause temporary discomfort, and teams use appropriate measures to improve comfort.

Some people feel unwell from treatment-related side effects rather than pain from the genetic therapy itself. Fatigue, fever, nausea or body aches can occur depending on the therapy and any preparatory medicines. Patients should tell the team promptly about pain or new symptoms so that they can be assessed and treated safely.

Before treatment, the care team should explain what sensations and side effects are most likely, how pain relief is managed and who to contact after discharge. Clear preparation can make the process feel more predictable and manageable.

When to seek medical care

Anyone considering genome therapy should seek assessment from a qualified specialist rather than pursuing unregulated products or clinics. A doctor can confirm whether a genetic diagnosis has been established, whether approved treatment or a clinical trial may be relevant, and what alternatives should be considered.

After treatment, urgent medical advice is needed for fever, chills, breathing difficulty, chest pain, severe or worsening headache, confusion, fainting, unusual bleeding, persistent vomiting or signs of infection. The treatment center will provide individualized emergency instructions, particularly for patients who have recently received conditioning chemotherapy or immune-cell therapy.

Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals support international patients who need assessment and treatment planning for complex conditions, including those that may be considered for advanced genetic therapies. Decisions should always be based on a personalized discussion of diagnosis, evidence, risks and follow-up needs.

Frequently asked questions